Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
6
-
Total 13F shares, excl. options
-
1.03M
-
Shares change
-
+1.03M
-
Total reported value, excl. options
-
$3M
-
Value change
-
+$3M
-
Number of buys
-
6
-
Price
-
$2.91
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q4 2018
6 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q4 2018.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 6 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.03M shares
of 51.9M outstanding shares and own 1.99% of the company stock.
Largest 7 shareholders include WEXFORD CAPITAL LP (475K shares), G2 Investment Partners Management LLC (220K shares), Manatuck Hill Partners, LLC (200K shares), Worth Venture Partners, LLC (130K shares), BANK OF AMERICA CORP /DE/ (5.9K shares), UBS Group AG (1.32K shares), and ROYAL BANK OF CANADA (503 shares).
This table shows the top 6 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.